Anderman Jonathan 4
4 · Compass Therapeutics, Inc. · Filed Apr 29, 2026
Research Summary
AI-generated summary of this filing
Compass Therapeutics GC Jonathan Anderman Receives RSU Award
What Happened Jonathan Anderman, General Counsel of Compass Therapeutics (CMPX), was granted 25,000 shares on 2026-04-29 reported at $1.89 per share, a total reported value of $47,250. The filing shows this as an award/grant (transaction code A), not an open-market purchase or sale — i.e., compensation rather than a cash purchase.
Key Details
- Transaction date and type: 2026-04-29 — Award/Grant (Code A).
- Shares and value: 25,000 shares at $1.89 per share; total reported value $47,250.
- Shares owned following transaction: Not disclosed in the filing.
- Footnote (F1): The filing notes 150,000 of the shares are unvested restricted stock units (RSUs) granted on January 2, 2026; each RSU is a contingent right to one share and vests in four equal annual installments, with the first vesting on January 2, 2027.
- Timeliness: Report period and filing date are both 2026-04-29 (timely filing).
- No 10b5-1 plan, tax withholding, or immediate sale reported in this transaction.
Context This was an RSU award (compensation) rather than a market purchase; RSUs are subject to vesting and typically do not reflect an immediate investment of personal cash. Awards are common executive compensation and should be interpreted differently from insider purchases or sales — they disclose potential future share issuance contingent on service/vesting.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-29$1.89/sh+25,000$47,250→ 196,000 total
Footnotes (1)
- [F1]150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.